Full Coverage

Novo Nordisk weight-loss drug trials

Top news

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

By Stine Jacobsen & Maggie Fick

Novo Nordisk’s amylin obesity drug keeps performing like Zepbound

3 days ago

By Elaine Chen

Novo Nordisk Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts.

2 days ago

By Mackenzie Tatananni

Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints

2 days ago

By Aaron McDade

All coverage

Significant Weight Loss With CagriSema, But Less Than Hoped

2 days ago

By Alicia Ault

Ozempic maker announces not one, but three new weight-loss drugs

2 days ago

By Bronwyn Thompson

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

3 days ago

By Kristen Monaco

Novo Nordisk Obesity Shot Tied to Greater Weight Loss at Lower Doses

2 days ago

By Naomi Kresge & Catherine Larkin

Diabetes Dialogue: REDEFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD

3 days ago

By Melanie Davies, W. Timothy Garvey & Diana Isaacs

FirstWord Pharma

Spotlight On: ADA updates fail to lift cautious mood around Novo Nordisk's next-generation obesity drugs

2 days ago

Amylin Analogue Boosts Weight Loss When Added to GLP1

17 hours ago

Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III

2 days ago

By Tristan Cesar Manalac

Cagrilintide and semaglutide together drive record weight loss in global trial

2 days ago

By Vijay Kumar Malesu

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

3 days ago

The Globe and Mail

Why Novo Nordisk Stock Is Sinking Today

2 days ago

ADA: Novo continues effort to rehabilitate CagriSema

2 days ago

The Pharma Letter

New data on Novo’s next-gen obesity drugs and hemophilia challenger

2 days ago

Financial Times

Novo hunts for ‘maximum potential’ from obesity drug CagriSema

3 days ago

By Hannah Kuchler

ADA 2025: CagriSema Demonstrates Significant Weight Loss in REDEFINE Clinical Trials

3 days ago

By Kennedy Ferruggia

Why Novo Nordisk Stock Sank by Nearly 4% Today

9 days ago

By Eric Volkman

Novo Nordisk (NVO) Achieves Significant Weight Loss Results in Phase 3 Trial | NVO Stock News

2 days ago

Novo Nordisk starts new CagriSema weightloss drug trial

2 days ago

By Stine Jacobsen, Maggie Fick & Kirsten Donovan

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern - Novo Nordisk (NYSE:NVO)

2 days ago

By Vandana Singh

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

3 days ago

Novo Nordisk presents detailed data on weight loss candidate cagrisema

2 days ago

Eli Lilly Stock (LLY) Pops as Weight-Loss Drug Data from Rival Novo Nordisk Disappoints

2 days ago

By Joel Baglole

Novo Nordisk Struggles With CagriSema's Competitive Edge

2 days ago

Novo Nordisk: positive data on CagriSema in the NEJM

2 days ago

PR Newswire Canada

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Yesterday

Proactive financial news

Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautious

2 days ago

By Ian Lyall

Investing.com Nigeria

Novo Nordisk falls as CagriSema obesity data shows no clear edge vs Zepbound

2 days ago

By Navamya Acharya

Longview News-Journal

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

3 days ago

Investor Concerns Rise Over Novo Nordisk's CagriSema Trial Results - News and Statistics

2 days ago

NVO Stock Drops Amid Partnership Termination and Trial Results

2 days ago

Novo Nordisk announces REDEFINE 1 trial of CagriSema met co-primary endpoints

3 days ago

Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints

2 days ago

By Aaron McDade

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

3 days ago

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

By Stine Jacobsen & Maggie Fick

The Motley Fool

Why Novo Nordisk Stock Is Sinking Today

2 days ago

By Johnny Rice

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

3 days ago

By Deena Beasley & Franklin Paul

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny By Reuters

2 days ago

By Stine Jacobsen & Maggie Fick

ADA 2025: CagriSema Demonstrates Dual Benefit in Obesity and Type 2 Diabetes

3 days ago

By Patrick Campbell

Why Novo Nordisk Stock Is Sinking Today

2 days ago

By Johnny Rice

Why Novo Nordisk Stock Is Sinking Today

2 days ago

By Johnny Rice

Why Novo Nordisk Stock Is Sinking Today

2 days ago

By Johnny Rice

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

By Stine Jacobsen & Maggie Fick

Why Novo Nordisk Stock Sank by Nearly 4% Today

2 days ago

By Eric Volkman

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

By Stine Jacobsen & Maggie Fick

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

By Stine Jacobsen, Maggie Fick & Jan Harvey

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

2 days ago

By Stine Jacobsen & Maggie Fick

Novo Nordisk Shares Fall as Obesity Pipeline Faces Investor Scrutiny

2 days ago

By Stine Jacobsen, Maggie Fick & Jan Harvey

Search

Clear search

Close search

Google apps

Main menu